Skip to content
Capivasertib
Capivasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-beta serine/threonine-protein kinase, RAC-gamma serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C507102——16
Prostatic neoplasmsD011471C61341——7
Triple negative breast neoplasmsD064726231——4
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8041———5
Ovarian neoplasmsD010051EFO_0003893C5622———3
Non-small-cell lung carcinomaD002289—2———2
AdenocarcinomaD000230—2———2
Endometrial neoplasmsD016889EFO_000423011———2
Stomach neoplasmsD013274EFO_0003897C16—2———2
Multiple myelomaD009101C90.0—2———2
LymphomaD008223C85.9—2———2
Uterine cervical neoplasmsD00258311———2
Endometrioid carcinomaD01826912———2
Show 18 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—5————5
PharmacokineticsD0105992————2
Hematologic neoplasmsD0193371————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCAPIVASERTIB
INNcapivasertib
Description
Capivasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-beta serine/threonine-protein kinase, RAC-gamma serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase.
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1
Identifiers
PDB—
CAS-ID1143532-39-1
RxCUI—
ChEMBL IDCHEMBL2325741
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDWFR23M21IE (ChemIDplus, GSRS)
Target
Agency Approved
AKT2
AKT2
AKT3
AKT3
AKT1
AKT1
Organism
Homo sapiens
Gene name
AKT2
Gene synonyms
NCBI Gene ID
208
Protein name
RAC-beta serine/threonine-protein kinase
Protein synonyms
murine thymoma viral (v-akt) homolog-2, PKB beta, Protein kinase Akt-2, Protein kinase B beta, putative v-akt murine thymoma viral oncoprotein 2, rac protein kinase beta, RAC-PK-beta, v-akt murine thymoma viral oncogene homolog 2
Uniprot ID
P31751
Mouse ortholog
Akt2 (11652)
RAC-beta serine/threonine-protein kinase (Q60823)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 632 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10 adverse events reported
View more details